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Abstract
Objective: To assess the risk of developing high-grade cervical dysplasia among women with low-grade cervical cytology
and nonvisible squamocolumnar junction (SCJ) at colposcopic examination. Methods: Data of consecutive women with low-
grade intraepithelial lesion(LSIL) undergoing colposcopic examination, which was unsatisfactory (due to the lack of the
visualization of the entire SCJ), were retrospectively reviewed. The risk of developing high-grade cervical intraepithelial
neoplasia (CIN2þ) was assessed using Kaplan-Meier and Cox models. Results: Data of 86 women were retrieved. Mean
(standard deviation [SD]) age was 36.3 (13.4) years. A total of 71 (82.5%) patients had high-risk human papillomavirus (HR-HPV) at
the time of diagnosis. Among the 63 patients undergoing repetition of HPV testing, 15 (24%) and 48 (76%) women had positive and
negative tests for HR-HPV at 12 months, respectively. We observed that 5 (33%) of 15 patients with HPV persistence developed
CIN2þ, while only 1 (2%) patient of 48 patients without HPV persistence developed CIN2þ (odds ratio [OR]: 23.5; 95% con-
fidence interval [CI]: 2.46-223.7; P < .001). The length of HR-HPV persistence correlated with an increased risk of developing
CIN2þ (P < .001; P for trend). High-risk HPV persistence is the only factor predicting for CIN2þ (hazard ratio: 3.19; 95% CI: 1.55-
6.57; P ¼ .002). Conclusions: High-risk HPV persistence predicts the risk of developing CIN2þ in patients with unsatisfactory
colposcopic examination. Further studies are warranted in order to implement the use of HPV testing in patients with unsa-
tisfactory colposcopy.
Keywords
HPV, high-grade dysplasia, unsatisfactory colposcopy, CIN
Introduction
Colposcopy allows identification of abnormal areas, including
low- and high-grade cervical intraepithelial neoplasia (CIN1 and
CIN2þ, respectively).1-3 Lesions are generally located in the
transformational zone (TZ) close to the squamocolumnar junc-
tion (SCJ).4 The evaluation of TZ and SCJ is paramount to assess
the status of the uterine cervix, in case of human papillomavirus
(HPV) infection. Therefore, the visualization of the SCJ is essen-
tial to assess the quality of colposcopic examination.
According to the old nomenclature, the lack of the visualiza-
tion of the entire SCJ defined a colposcopy as “unsatisfactory.”
Although the new nomenclature refused the term “unsatisfactory
colposcopy,” the not complete visualization of the SCJ is
still a concern.
It is estimated that the entire SCJ is not visualized in about
10% to 20% of colposcopic examinations, thus making these
evaluation less precise than in case in which the SCJ is fully
visualized. Several investigators recommended cone biopsy in
those cases.5,6
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In the present study, we sought to assess the risk of
developing high-grade lesions (CIN2þ) among women with
low-grade cervical cytology and unsatisfactory colposcopic
examination. Additionally, we aimed to identify factors pre-
dicting CIN2þ among this cluster of women.
Methods
We retrospectively reviewed records of all consecutive
women undergoing HPV DNA testing between 2005 and
2015 at Gynecologic Oncology Unit of National Cancer
Institute (Milan, Italy). The institutional review board
approved this study.
Data of all patients included were abstracted from a dedi-
cated database including all women undergoing HPV testing.
Data were included prospectively into the database. All
patients included gave written informed consent for the use
of personal information for health research. Demographic
details, data about HPV type(s) detected, and data on treatment
for the occurrence of genital precancerous and cancerous con-
dition were retrospectively reviewed. Low-grade cervical
cytology included low-grade intraepithelial lesion (LSIL) and
atypical squamous cells of undetermined significance. Unsatis-
factory colposcopy was defined according to the old nomen-
clature realized by the International Federation for Cervical
Pathology and Colposcopy (IFCPC).4 Human papillomavirus
types were considered as high risk (HR) according to the data
of the International Agency for Research on Cancer.7 High-risk
HPV types classified as type 1 carcinogens included HPV16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66. Figure 1 shows
the flow of patients into the study design.
Age was categorized as the follows: age less than 30 years,
between 30 and 50 years, and more than 50 years. On the basis
of body mass index (BMI), women were categorized into
normal weight (BMI less than 25 kg/m2), overweight (BMI
more than 25 less than 30 kg/m2), and obese (BMI more than
30 kg/m2). Tobacco use was defined as a dichotomous vari-
able (yes vs no). Exclusion criteria were as follows: (1) age
younger than 18 years, (2) withdrawal of consent, (3) history
of HPV-related lesions (including cervical, vaginal, and vul-
var dysplasia related to HPV infections) within the past 5
years, (4) pregnancy, and (5) previous hysterectomy. Accord-
ing to our institutional protocol, patients were evaluated col-
poscopically in outpatient clinic at 6 months after primary
colposcopic examination. A dedicated team of gynecologic
oncologists performed all gynecological and colposcopic
examinations. Details regarding colposcopic examination,
HPV testing, and HPV analysis are reported elsewhere.8 The
genotyping results were ranked hierarchically according to
cancer risk: HPV 16 > HPV 18 > other carcinogenic HPV.
Generally, HPV testing was performed at the time of first
colposcopic examination. In our department, no specific
guidelines suggested the repetition of HPV testing. However,
the majority of women with the diagnosis of HR-HPV had
another HPV testing at 6 or 12 months after primary exam-
ination.8 Human papillomavirus infection persistence was
defined as the persistence of an HPV type, detected at 2 con-
secutive time points, in accordance with the definition
included in the meta-analysis of Koshiol et al.9
Data are summarized using basic descriptive statistics. The risk
of developing CIN2þ was evaluated using Kaplan-Meir and Cox
models. Hazard ratio and 95% confidence intervals (CIs) were
Figure 1. Study design.
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calculated for each comparison. Univariate and multivariate anal-
yses were performed when appropriate. All covariates with a P
value less than .10, based on univariate analysis, were included in
the multivariate model. Duration of follow-up was counted from
date of LSIL detection and of CIN2þ diagnosis or date of last
follow-up. Statistical analyses were performed using GraphPad
Prism version 6.0 for Mac (GraphPad Software, San Diego, Cali-
fornia) and IBM-Microsoft SPSS (SPSS Statistics. International
Business Machines Corporation IBM. 2013. Armonk) version
20.0 for Mac.
Results
Data of 86 women diagnosed with low-grade cervical cytology
were retrieved. Table 1 reports baseline characteristics of the
study population. Mean (standard deviation [SD]) age was 36.5
(12.1) years. Seventy-one (82.5%) patients had HR-HPV at the
time of diagnosis. Among the 63 patients undergoing repetition
of HPV testing, 15 (24%) and 48 (76%) women had positive
and negative tests for HR-HPV at 12 months, respectively.
After a median follow-up of 29 (75% interquartile range: 23-
60) months, 8 (9.3%) patients had conization due to CIN2þ
(data not shown). No invasive cancer was diagnosed.
Table 2 reports factors predicting the risk of developing
CIN2þ. Considering factors predicting the risk of developing
CIN2þ over time (median follow-up: 29 months), HR-HPV
persistence correlated with the risk of developing CIN2þ
(hazard ratio: 3.19; 95% CI: 1.55-6.57; P ¼ .002). Similarly,
length of HR-HPV persistence correlated with an increased risk
of developing CIN2þ (P < .001; P for trend—data not shown).
No other factors correlated with the risk of developing CIN2þ.
However, although it did not reach statistical significance, we
observed that women with overweight (BMI between 25 and 30
kg/m2) experienced a higher risk of developing CIN2þ (hazard
ratio: 2.72; 95% CI: 0.54-13.6; P ¼ .22).
Looking at the crude number of CIN2þ diagnosed, we
observed that 5 (33%) of 15 patients with HPV persistence at
12 months developed CIN2þ, while only 1 (2%) of 48 patients
without HPV persistence developed CIN2þ (odds ratio: 23.5;
95% CI: 2.46-223.7; P < .001; Table 2). Type-specific HR-
HPV infection did not influence the risk of developing CIN2þ.
In fact, comparing women having an infection from HPV 16,
HPV 18, and other HR-HPV types, we observed a similar risk
at 10-year follow-up (P ¼ .89, log-rank test). Similarly, no
differences were observed comparing HPV 16 and HPV 18
(P ¼ .61, log-rank test).
Discussion
The present study evaluated outcomes of women diagnosed
with low-grade cervical cytology and characterized by an unsa-
tisfactory colposcopic examination, thus reporting a number of
noteworthy findings. First, we observed that women diagnosed
with low-grade cervical cytology have a risk of about 30% of
developing CIN2þ in case of positivity for HR-HPV, while in
the absence of HR-HPV infection, this risk is negligible. Sec-
ond, persistence of HR-HPV is the main factor predicting this
risk. Third, type-specific HPV infection does not influence
Table 1. Baseline Patient Characteristics.
Characteristics N ¼ 86
Age, median (IQR), years 32.5 (26, 45.2)
BMI, median (IQR), kg/m2 22 (21, 24.2)
Tobacco use, n (%)
No 68 (79%)
Yes 18 (21%)
Positivity for HPV at diagnosis, n (%) 71 (82.5%)
Positivity for HPV 16/18 at diagnosis, n (%) 37 (43%)
Positivity for HPV other than 16/18 at diagnosis, n (%) 34 (39.5%)
Patients undergoing another HPV testing after
primary examination
63 (73.2%)
Persistence of HPV, n (%) 15 (17.4%)
Time of HPV persistence, median (IQR), months 6 (6-18)
Follow-up, median (IQR), months 29 (23-60)
Abbreviations: BMI, body mass index; HPV, human papillomavirus; IQR,
interquartile range; SD, standard deviation.
Table 2. Factors Influencing the Risk of Developing CIN2þ.a
Characteristics
Number
of
Patients
Number
of
CIN2þ
Univariate
Analysis, HR
(95% CI)
P
Value
Age, years
Less than 30 years 33 4 (12.1%) 1.54 (0.38-6.19) .53
Between 30 and
50 years
39 2 (5.1%) 0.42 (0.08-2.09) .29
More than 50 years 14 2 (14.3%) 1.66 (0.33-8.23) .53
BMI, kg/m2
Normal weight 54 4 (7.4%) 0.78 (0.24-5.59) .12
Overweight 20 3 (15%) 2.72 (0.54-13.6) .22
Obese 13 1 (7.7%) 0.04 (0.00-488.3) .50
Tobacco use .52
No 68 7 (10.3%) Reference
Yes 18 1 (5.5%) 0.50 (0.06-4.08)
Positivity for HR-HPV
at diagnosis
.79
No 15 1 (6.7%) Reference
Yes 71 7 (9.8%) 1.32 (0.16-10.8)
Positivity for HPV
16/18 at diagnosis
.76
No 49 5 (10.2%) Reference
Yes 37 3 (8.1%) 0.80 (0.19-3.37)
Positivity for HR-HPV
other than 16/18 at
diagnosis
.73
No 52 4 (7.7%) Reference
Yes 34 4 (11.7%) 0.73 (0.31-5.11)
HR-HPV persistence .002
No 48 1 (2%) Reference
Yes 15 5 (33%) 3.19 (1.55-6.57)
Abbreviations: BMI, body mass index; CI, confidence interval; CIN, cervical
intraepithelial neoplasia; HPV, human papillomavirus; HR, hazard ratio; HR-
HPV, high-risk human papillomavirus.
aVariables characterized by P value < .10 are presented in bold characters.
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patient outcomes. Additionally, in our series, other baseline
factors (such as age or BMI) do not impact on the risk of
developing CIN2þ.
In the present study, we analyzed a particular subset of
patients for whom colposcopic examination was not able to
define the entire SCJ. According to the nomenclature intro-
duced in 2002, these colposcopic examinations are defined
as “unsatisfactory.” On the other hand, colposcopy was
defined “satisfactory” in case of complete visualization of
the SCJ. In 2011, the new nomenclature realized by the
IFCPC replaced the terms “satisfactory colposcopy” and
“unsatisfactory colposcopy” with different degree of SCJ
visibility. The term “unsatisfactory colposcopy” was aban-
doned because it has the connotation of an inadequate
examination that needs to be repeated.4
Recently, an investigation published by our study group
evaluated the risk of developing CIN2þ in consecutive 212
women diagnosed with high-risk HPV types with negative
cytology results. We observed that HPV persistence correlated
with both LSIL/CIN1þ (P < .001) and CIN2þ (P < .001) in
univariate analyses. Moreover, a 6-month increase in HPV
persistence was associated with increased risk of developing
LSIL/CIN1þ (P¼ .010) and CIN2þ (P¼ .012) in multivariate
analyses.10 The data reported in this previous investigation are
in agreement with those reported in the present study.
Although several studies investigated the rate of occult
CIN2þ diagnosed in women with high-risk cytology and unsa-
tisfactory colposcopy,11-14 the present study is the first inves-
tigating the risk of developing CIN2þ over time in women for
whom the trigger pap smear indicated the presence of low-
grade abnormalities. Our data will be useful during patients’
counseling. Obviously, our findings have to be confirmed by
larger prospective investigations.
Interestingly, our study suggested that there was no differ-
ence between HPV 16 to HPV 18 versus other HR-HPV types
in predicting the risk of developing CIN2þ. We observed that
in a 10-year follow-up, there was no difference between differ-
ent HPV types involved. This finding is in contrast with other
results published in the literature.15 In fact, accumulating evi-
dence suggested that HPV 16 and HPV 18 correlate with a
greater risk of developing cervical dysplasia in comparison
with other HPV types.15 However, the relative small sample
size of the 2 subgroups of patients (HPV 16-HPV 18 vs other
HR-HPV types) might influence this finding.
The inherent biases of the single-center retrospective study
design are the main weaknesses of the present study. The main
strength of the present investigation is represented by the
potential clinical implication of our results. In fact, our data
might be useful for patients’ counseling and scheduling their
follow-up. Four points of the present investigation deserve to
be addressed: (1) we observed the patients diagnosed with a
low-risk cervical cytology experienced a relative high risk of
developing CIN2þ, in case of HR-HPV persistence. However,
owing to the small sample size and the relative low power of
the study, these data have to be confirmed in other large inves-
tigations. (2) Our experience might not reflect the common
practice since our study population is a selected group of
patients referred into a National Cancer Center, instead of
territorial centers. (3) In our analysis, type-specific HPV
types are not associated with the risk of developing CIN2þ.
Other experiences suggested that type-specific HPV type(s)
correlates with patient outcomes.8,13,14 (4) Smoking history
might impact on patient outcomes. In the present study,
tobacco use was defined as a dichotomous variable (yes
vs no). We might speculate that magnitude of tobacco use
as well as length of smoking might influence how this vari-
able impact on our results.
In conclusion, the present study reported outcomes of
women who had unsatisfactory colposcopy after the diagnosis
of low-grade cervical cytological abnormalities. Our analysis
suggested that HR-HPV persistence is the main factor predict-
ing for the occurrence of CIN2þ. In case of HR-HPV persis-
tence, the risk of developing CIN2þ is not negligible. Further
prospective studies are warranted in order to improve treat-
ments of women with unsatisfactory colposcopy.
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